tiprankstipranks
Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), TruBridge (TBRG) and Ligand Pharma (LGND)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLYResearch Report), TruBridge (TBRGResearch Report) and Ligand Pharma (LGNDResearch Report).

Eli Lilly & Co (LLY)

In a report released today, Carter Gould from Barclays maintained a Buy rating on Eli Lilly & Co, with a price target of $913.00. The company’s shares closed last Friday at $760.00, close to its 52-week high of $800.78.

According to TipRanks.com, Gould is a 4-star analyst with an average return of 7.7% and a 51.5% success rate. Gould covers the Healthcare sector, focusing on stocks such as Barinthus Biotherapeutics, Travere Therapeutics, and Bristol-Myers Squibb.

Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $891.59, representing a 15.2% upside. In a report issued on April 30, Citi also upgraded the stock to Buy with a $895.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

TruBridge (TBRG)

In a report released today, Stephanie Davis from Barclays maintained a Hold rating on TruBridge, with a price target of $10.00. The company’s shares closed last Friday at $8.77, close to its 52-week low of $7.55.

According to TipRanks.com, Davis has 0 stars on 0-5 stars ranking scale with an average return of -7.2% and a 39.0% success rate. Davis covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, Lifestance Health Group, and Quest Diagnostics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TruBridge with a $11.50 average price target.

Ligand Pharma (LGND)

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Ligand Pharma, with a price target of $110.00. The company’s shares closed last Friday at $87.28, close to its 52-week high of $94.57.

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 3.5% and a 44.8% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Dr Reddy’s Laboratories, Amneal Pharmaceuticals, and Tarsus Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ligand Pharma with a $121.00 average price target, which is a 41.5% upside from current levels. In a report issued on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $144.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LLY:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles